Lexicon Pharmaceuticals, Inc..
LXRX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines to treat diseases. The company's key focus areas include treatments for diabetes, cancer, and other human diseases. Lexicon utilizes its proprietary gene knockout...Show More
Better Health for All
-40
Lexicon Pharmaceuticals' core products and pipeline are dedicated to treating serious diseases. Sotagliflozin (INPEFA) has demonstrated significant health benefits, including reducing major adverse cardiovascular events (MACE) by 23% (4.8 events per 100 person-years vs. 6.3 for placebo), myocardial infarction by 32% (1.8 vs. 2.7), and stroke by 34% (1.2 vs. 1.8).
1
It also increased quality-adjusted life-years (QALYs) by 0.425 compared to standard of care.
2
Xermelo treats carcinoid syndrome diarrhea,
3
and investigational pilavapadin showed pain score reductions of up to 1.74 points compared to 1.31 for placebo in diabetic peripheral neuropathic pain patients.
4
All products are intended for health improvement, with no revenue from products with net negative health outcomes. However, sotagliflozin carries known risks including ketoacidosis, acute kidney injury, volume depletion, urosepsis, pyelonephritis, Fournier's gangrene, and genital mycotic infections, with an increased risk of diabetic ketoacidosis (DKA) in type 1 diabetes patients.
5
The company has developed an educational plan for patients and healthcare providers on the potential risks and appropriate use of sotagliflozin.
6
The company's investigational drug pilavapadin is a non-opioid, aiming to reduce reliance on opioids for pain management.
7
The company focuses on high-risk populations like type 1 diabetes patients with chronic kidney disease, but specific data on the percentage of vulnerable populations reached is not provided.
8
The company's R&D efforts are focused on developing new treatments for diabetes and pain, including three phase 3 studies for sotagliflozin involving nearly 3,000 adults with type 1 diabetes
9
and a Phase 2b study for pilavapadin with 496 adult patients.
10
Fair Money & Economic Opportunity
0
No evidence available to assess Lexicon Pharmaceuticals, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess Lexicon Pharmaceuticals, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No specific, concrete data points were found across the provided articles to assess Lexicon Pharmaceuticals, Inc. against any of the KPIs for Fair Trade & Ethical Sourcing. The articles primarily contain financial data, regulatory actions related to drug applications, and general information about supplier codes of conduct or industry practices, none of which provide measurable evidence for fair trade certification, audit frequency, forced/child labor incidents, supply chain traceability, remediation speed, ethical clause coverage, materials risk, or supplier diversity spend for LXRX.US.
1
Honest & Fair Business
0
No specific, concrete evidence was found in the provided articles to score any of the KPIs for Honest & Fair Business. The articles either explicitly state a lack of quantitative data, do not contain relevant information, or were inaccessible due to throttling.
1
Kind to Animals
-20
Lexicon Pharmaceuticals conducts pre-clinical trials on animals, including mice, rats, and dogs, and generates gene function discoveries using knockout mice.
1
All studies performed at Lexicon Pharmaceuticals are approved by the Lexicon Institutional Animal Care and Use Committee (IACUC), holding OLAW Assurance Number A4152-01 and AAALAC International Accreditation Number 001025.
2
All work is performed in accordance with Public Health Service policies and the Animal Welfare Act.
3
The company's policy prohibits discretionary testing, but legal mandates still override alternatives. Lexicon uses animals in testing, with mice (68%) and rats (15%) being the most common species.
4
The company participates in international consortia like EUMODIC, established to analyze mutant phenotypes in detail.
5
No War, No Weapons
0
No evidence available to assess Lexicon Pharmaceuticals, Inc. on No War, No Weapons.
Planet-Friendly Business
0
The provided articles do not contain specific, quantitative data points for any of the Planet-Friendly Business KPIs. Information available focuses on general ESG risk ratings and overall impact scores, but lacks details on environmental performance metrics such as emissions, renewable energy use, water consumption, waste diversion, or climate targets.
1
Therefore, no KPIs can be scored based on the evidence provided.
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles for any of the KPIs related to 'Respect for Cultures & Communities'. The articles primarily consist of financial reports, clinical trial information, or general discussions on health equity and digital inclusion, none of which contain evidence regarding community engagement, cultural impact assessments, local employment, grievance mechanisms, or other relevant metrics for Lexicon Pharmaceuticals.
1
Safe & Smart Tech
0
No evidence available to assess Lexicon Pharmaceuticals, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
There is insufficient evidence to assess Lexicon Pharmaceuticals' alignment with zero waste and sustainable product practices. The provided article is a placeholder and contains no relevant data regarding waste diversion rates, product recyclability, packaging sustainability, or other relevant metrics.
1
Therefore, a neutral score is assigned. The materiality analysis indicates that the pharmaceutical industry has waste concerns in R&D, manufacturing and packaging, but without specific data, a proper assessment cannot be made.